53 completed, 15 terminated, 10 recruiting, 4 active not recruiting. 41 Phase 3, 15 Phase 4, 8 Phase 2, 2 Not applicable, 2 Phase 1.
By phase and status
| Phase | Trials | Status |
|---|
| Phase 3 | 41 | Completed 29, Recruiting 5, Terminated 5, Active not recruiting 1, Unknown 1 |
| Phase 4 | 15 | Completed 7, Terminated 3, Recruiting 2, Unknown 2, Withdrawn 1 |
| Phase 2 | 8 | Completed 4, Terminated 2, Unknown 1, Withdrawn 1 |
| Not applicable | 2 | Completed 2 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow Octapharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections
Panzyga, 10% Intravenous Solution, Placebo - Hypogammaglobulinemia, Autoimmune Conditions | Phase 3 | Recruiting | Octapharma | 360 | 2026-06-10 | 2026-09-29 |
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
Nuwiq - Hemophilia A | Phase 4 | Recruiting | Octapharma | 28 | 2026-04-01 | 2026-05-12 |
Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
Balfaxar, Kcentra - Vitamin K-Dependent Coagulation Defect, Significant Bleeding Risk | | Active not recruiting | Octapharma | 3574 | 2025-02-14 | 2026-09-15 |
Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
Human plasma derived antithrombin, Placebo - Acquired Antithrombin Deficiency | Phase 3 | Recruiting | Octapharma | 120 | 2024-08-21 | 2026-09-28 |
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
OCTA-C1-INH, Placebo - Acute Hereditary Angio Edema | Phase 3 | Recruiting | Octapharma | 124 | 2024-04-30 | 2026-09-29 |
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
Nuwiq - Severe Hemophilia A | Phase 4 | Recruiting | Octapharma | 28 | 2023-11-28 | 2026-05-12 |
Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Panzyga - Pediatric Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | Recruiting | Octapharma | 30 | 2023-10-01 | 2026-08-05 |
Observational Study of Subcutaneous Immunoglobulin (Cutaquig) in Patients With Primary and Secondary Immunodeficiency.
Cutaquig® - Primary Immune Deficiency Disorder, Secondary Immune Deficiency | | Active not recruiting | University of Alberta | 36 | 2023-04-01 | 2026-05-08 |
Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery
Octaplex, Frozen Plasma Product, Human - Bleeding Cardiac Surgery Patients | Phase 3 | Completed | Octapharma | 420 | 2022-11-30 | 2025-08-15 |
Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery
Atenativ - Congenital Antithrombin Deficiency | Phase 3 | Recruiting | Octapharma | 38 | 2022-07-01 | 2026-09-28 |
Comparison of Fibrinogen Concentrate and Cryoprecipitate in Pediatric Cardiac Surgery Patients
Fibrinogen, Cryoprecipitate - Pediatric HD, Bleeding | Phase 4 | Completed | University of Virginia | 31 | 2021-10-26 | 2026-03-06 |
Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age
Wilate - Von Willebrand Disease | Phase 3 | Completed | Octapharma | 12 | 2021-09-22 | 2026-02-20 |
Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor
Octaplex - Acute Major Bleeding | Phase 3 | Terminated | Octapharma | 100 | 2021-09-01 | 2026-06-25 |
Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases
Newnorm - Primary Immune Deficiency | Phase 3 | Active not recruiting | Octapharma | 50 | 2021-08-04 | 2026-08-06 |
Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)
Panzyga, Placebo - Pediatric Acute-Onset Neuropsychiatric Syndrome | Phase 3 | Completed | Octapharma | 71 | 2021-06-30 | 2026-01-07 |
Factor In the Initial Resuscitation of Severe Trauma 2 Patients
Fibrinogen + PCC, Frozen Plasma - Traumatic Hemorrhage, Coagulopathy | Phase 4 | Terminated | University Health Network, Toronto | 142 | 2021-04-01 | 2026-10-21 |
Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency
Fibryga - Congenital Fibrinogen Deficiency | | Terminated | Octapharma | 7 | 2021-01-28 | 2025-06-24 |
Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection
Antithrombin III - Covid19 | | Completed | Octapharma | 300 | 2020-10-19 | 2023-10-10 |
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)
Panzyga, Placebo - Chronic Lymphocytic Leukemia, Hypogammaglobulinemia | Phase 3 | Completed | Octapharma | 247 | 2020-10-05 | 2026-06-04 |
Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD
Wilate - Von Willebrand Diseases | Phase 3 | Completed | Octapharma | 43 | 2020-06-18 | 2023-10-25 |
Showing 20 of 87. Sign in to see all of them.
Conditions studied
Hemophilia A (17) · Primary Immunodeficiency Diseases (12) · von Willebrand Diseases (6) · Hemophilia B (4) · Hemostatic Disorders (4) · COVID-19 (3) · Purpura, Thrombotic Thrombocytopenic (3) · Agammaglobulinemia (2) · Antithrombin III Deficiency (2) · Dermatomyositis (2) · Hematologic Diseases (2) · Hemorrhage (2) · Pediatric acute-onset neuropsychiatric syndrome (2) · Purpura, Thrombocytopenic, Idiopathic (2) · Shock, Septic (2)
Interventions
von Willebrand Factor (8) · Factor VIII (7) · Panzyga (7) · prothrombin complex concentrates (5) · Antithrombin III (3) · Fibrinogen (3) · Immunoglobulins, Intravenous (3) · Factor IX (2) · Injections (2) · Octagam (2) · Saline Solution (2) · gamma-Globulins (2) · F8 protein, human (1) · Immunoglobulins (1) · Immunologic Tests (1)
Countries
United States (51) · Germany (22) · France (20) · Canada (16) · Russia (16) · United Kingdom (16) · Bulgaria (15) · Poland (13) · Ukraine (13) · Italy (12) · Hungary (11) · Austria (10) · Czechia (10) · Spain (10) · Romania (9)
Top investigators
Wolfgang Frenzel (7) · Wolfgang Frenzel, MD (7) · Cristina Solomon, MD (5) · Sigurd Knaub, PhD (4) · A. O. Gaber, MD (1) · Abdulgabar Salama, MD (1) · Barbara A Konkle, M.D. (1) · Boris Bienvenu, MD (1) · Bruce Ritchie, MD (1) · Christian G Bien, M.D. (1) · Courtney Thornburg, MD, MS (1) · Craig M Kessler, MD (1) · Cristina Solomon (1) · George Sakoulas, MD (1) · Guillaume Lefevre, MD (1)
Results publications
PMID 38237075, PMID 38353301, PMID 11057854, PMID 14719181, PMID 15500369, PMID 17636190, PMID 18226126, PMID 20863431, PMID 2329037, PMID 23320451, PMID 23375965, PMID 29855752, PMID 29863610, PMID 30687970, PMID 30778345, PMID 32212944, PMID 33042916, PMID 33429735, PMID 33601937, PMID 34479938, PMID 34589194, PMID 35038723, PMID 36198179, PMID 36285530, PMID 37180427, PMID 37378806, PMID 37799613, PMID 38233885, PMID 39088218, PMID 39174056, PMID 39624518, PMID 39918968, PMID 40156829, PMID 40616720, PMID 40982282, PMID 41151952, PMID 41278463, PMID 41614378, PMID 42404094, PMID 6484893, PMID 6618278, PMID 6872275
NIH funding
2009 (2), 2017 (1)